Pharmula Acquisition To Provide US Expansion Base For Jingxin
This article was originally published in PharmAsia News
Executive Summary
Shanghai-listed Jingxin Pharmaceutical is aiming to tap into the US market for its growing formulations business through the majority acquisition of Pharmula, a US-based contract services firm. The Chinese manufacturer is looking to capitalize on its partners’ strength in R&D to facilitate its global expansion.